Dynamic changes in circulating miRNA levels in response to antitumor therapy of lung cancer; Experimental Lung Research; Vol. 42, № 2

Bibliografiske detaljer
Parent link:Experimental Lung Research
Vol. 42, № 2.— 2016.— [P. 95-102]
Institution som forfatter: Национальный исследовательский Томский политехнический университет Физико-технический институт Кафедра прикладной физики (№ 12)
Andre forfattere: Ponomareva A. A. Anastasiya Alekseevna, Morozkin E. S. Evgeny Sergeevich, Rykova E. Yu. Elena Yurjevna, Zaporozhchenko I. A. Ivan Andreevich, Skvortsova T. E. Tatyana Evaldovna, Dobrodeev A. Yu. Alexey Yurjevich, Zavyalov A. A. Alexander Alexandrovich, Tuzikov S. A. Sergey Alexandrovich, Vlassov V. V. Valentin Viktorovich, Cherdyntseva N. V. Nadezhda Viktorovna, Laktionov P. P. Pavel Petrovich, Choynzonov E. L. Evgeny Lkhamatsyrenovich
Summary:Title screen
Purpose: Expression levels of cancer-associated microRNAs were reported to be altered in serum/plasma samples from lung cancer patients compared with healthy subjects. The purpose of this study was to estimate the value of five selected miRNAs plasma levels as markers of response to antitumor therapy in lung cancer patients. Materials and Methods: Expression levels of miR-19b, miR-126, miR-25, miR-205, and miR-125b have been evaluated by quantitative reverse transcription PCR versus control miR-16 in blood plasma samples from 23 lung cancer (LC) patients. Plasma samples were obtained from LC patients before treatment (untreated-UT), within 30 days after completing two courses of chemotherapy (postchemotherapy-PC) and 15 days after surgery (postoperative-PO). Results: Repeated Measures ANOVA demonstrated that miR-19b expression levels were decreased in PC and increased in PO samples. These changes were characterized by a significant quadratic trend (p = 0.03). Expression levels of miR-125b increased both after chemotherapy and again after surgery and demonstrated a significant linear trend (p = 0.03). The miR-125b/miR-19b ratio changed during the course of the antitumor treatment with a significant linear trend (p = 0.04). Individual analysis in the groups of patients with partial response to chemotherapy and patients with stable or progressive disease showed different trends for miR-19b, miR-125b, and miR-125b/miR-19b ratio between the groups. The Kaplan–Meier survival curves demonstrated an association of miR-125b/miR-19b ratio value with the survival time without the tumor relapse (p < 0.1). Conclusions: Dynamic change of trends for miR-19b and miR-125b expression levels and miR-125b/miR-19b ratio in the blood plasma have shown a potentiality to discriminate types of response to antitumor therapy in lung cancer patients. Further in-depth investigation is needed to establish a direct link the miRNAs expression levels in blood plasma with therapy response and patient's survival.
Режим доступа: по договору с организацией-держателем ресурса
Sprog:engelsk
Udgivet: 2016
Fag:
Online adgang:http://dx.doi.org/10.3109/01902148.2016.1155245
Format: MixedMaterials Electronisk Book Chapter
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=648509

MARC

LEADER 00000naa0a2200000 4500
001 648509
005 20250221140446.0
035 |a (RuTPU)RU\TPU\network\13668 
090 |a 648509 
100 |a 20160523d2016 k||y0rusy50 ba 
101 0 |a eng 
102 |a GB 
135 |a drcn ---uucaa 
181 0 |a i  
182 0 |a b 
200 1 |a Dynamic changes in circulating miRNA levels in response to antitumor therapy of lung cancer  |f A. A. Ponomareva [et al.] 
203 |a Text  |c electronic 
300 |a Title screen 
330 |a Purpose: Expression levels of cancer-associated microRNAs were reported to be altered in serum/plasma samples from lung cancer patients compared with healthy subjects. The purpose of this study was to estimate the value of five selected miRNAs plasma levels as markers of response to antitumor therapy in lung cancer patients. Materials and Methods: Expression levels of miR-19b, miR-126, miR-25, miR-205, and miR-125b have been evaluated by quantitative reverse transcription PCR versus control miR-16 in blood plasma samples from 23 lung cancer (LC) patients. Plasma samples were obtained from LC patients before treatment (untreated-UT), within 30 days after completing two courses of chemotherapy (postchemotherapy-PC) and 15 days after surgery (postoperative-PO). Results: Repeated Measures ANOVA demonstrated that miR-19b expression levels were decreased in PC and increased in PO samples. These changes were characterized by a significant quadratic trend (p = 0.03). Expression levels of miR-125b increased both after chemotherapy and again after surgery and demonstrated a significant linear trend (p = 0.03). The miR-125b/miR-19b ratio changed during the course of the antitumor treatment with a significant linear trend (p = 0.04). Individual analysis in the groups of patients with partial response to chemotherapy and patients with stable or progressive disease showed different trends for miR-19b, miR-125b, and miR-125b/miR-19b ratio between the groups. The Kaplan–Meier survival curves demonstrated an association of miR-125b/miR-19b ratio value with the survival time without the tumor relapse (p < 0.1). Conclusions: Dynamic change of trends for miR-19b and miR-125b expression levels and miR-125b/miR-19b ratio in the blood plasma have shown a potentiality to discriminate types of response to antitumor therapy in lung cancer patients. Further in-depth investigation is needed to establish a direct link the miRNAs expression levels in blood plasma with therapy response and patient's survival. 
333 |a Режим доступа: по договору с организацией-держателем ресурса 
461 |t Experimental Lung Research 
463 |t Vol. 42, № 2  |v [P. 95-102]  |d 2016 
610 1 |a электронный ресурс 
610 1 |a труды учёных ТПУ 
610 1 |a плазма крови 
610 1 |a рак легких 
610 1 |a терапия 
610 1 |a диагностика 
701 1 |a Ponomareva  |b A. A.  |c biologist  |c expert of Tomsk Polytechnic University, candidate of biological sciences  |f 1985-  |g Anastasiya Alekseevna  |3 (RuTPU)RU\TPU\pers\36792  |9 19821 
701 1 |a Morozkin  |b E. S.  |g Evgeny Sergeevich 
701 1 |a Rykova  |b E. Yu.  |g Elena Yurjevna 
701 1 |a Zaporozhchenko  |b I. A.  |g Ivan Andreevich 
701 1 |a Skvortsova  |b T. E.  |g Tatyana Evaldovna 
701 1 |a Dobrodeev  |b A. Yu.  |g Alexey Yurjevich 
701 1 |a Zavyalov  |b A. A.  |g Alexander Alexandrovich 
701 1 |a Tuzikov  |b S. A.  |g Sergey Alexandrovich 
701 1 |a Vlassov  |b V. V.  |g Valentin Viktorovich 
701 1 |a Cherdyntseva  |b N. V.  |g Nadezhda Viktorovna 
701 1 |a Laktionov  |b P. P.  |g Pavel Petrovich 
701 1 |a Choynzonov  |b E. L.  |c physicist  |c chief expert of Tomsk Polytechnic University  |f 1952-  |g Evgeny Lkhamatsyrenovich  |3 (RuTPU)RU\TPU\pers\34575  |9 17937 
712 0 2 |a Национальный исследовательский Томский политехнический университет  |b Физико-технический институт  |b Кафедра прикладной физики (№ 12)  |3 (RuTPU)RU\TPU\col\18729  |9 27178 
801 2 |a RU  |b 63413507  |c 20160524  |g RCR 
856 4 |u http://dx.doi.org/10.3109/01902148.2016.1155245 
942 |c CF